- Home
- SER
as 11-14-2024 4:00pm EST
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | HUNTSVILLE |
| Market Cap: | 54.3M | IPO Year: | 2018 |
| Target Price: | N/A | AVG Volume (30 days): | 17.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.81 - $23.18 | Next Earning Date: | 11-12-2024 |
| Revenue: | $3,156,637 | Revenue Growth: | 2436.14% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Serina Therapeutics Inc. News
SER Breaking Stock News: Dive into SER Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
4 days ago
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
GlobeNewswire
a month ago
Serina Therapeutics to Present at the 14th Annual Injectables Summit
GlobeNewswire
2 months ago
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GuruFocus.com
3 months ago
Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER)
GlobeNewswire
3 months ago
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
4 months ago
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
GlobeNewswire
4 months ago
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
Compare SER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SER Serina Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.